z-logo
Premium
De Novo Design of Skin‐Penetrating Peptides for Enhanced Transdermal Delivery of Peptide Drugs
Author(s) -
Menegatti Stefano,
Zakrewsky Michael,
Kumar Sunny,
De Oliveira Joshua Sanchez,
Muraski John A.,
Mitragotri Samir
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201500634
Subject(s) - transdermal , peptide , keratin , permeation , drug delivery , chemistry , drug , pharmacology , biochemistry , medicine , membrane , organic chemistry , pathology
Skin‐penetrating peptides (SPPs) are attracting increasing attention as a non‐invasive strategy for transdermal delivery of therapeutics. The identification of SPP sequences, however, currently performed by experimental screening of peptide libraries, is very laborious. Recent studies have shown that, to be effective enhancers, SPPs must possess affinity for both skin keratin and the drug of interest. We therefore developed a computational process for generating and screening virtual libraries of disulfide‐cyclic peptides against keratin and cyclosporine A (CsA) to identify SPPs capable of enhancing transdermal CsA delivery. The selected sequences were experimentally tested and found to bind both CsA and keratin, as determined by mass spectrometry and affinity chromatography, and enhance transdermal permeation of CsA. Four heptameric sequences that emerged as leading candidates (ACSATLQHSCG, ACSLTVNWNCG, ACTSTGRNACG, and ACSASTNHNCG) were tested and yielded CsA permeation on par with previously identified SPP SPACE TM . An octameric peptide (ACNAHQARSTCG) yielded significantly higher delivery of CsA compared to heptameric SPPs. The safety profile of the selected sequences was also validated by incubation with skin keratinocytes. This method thus represents an effective procedure for the de novo design of skin‐penetrating peptides for the delivery of desired therapeutic or cosmetic agents.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here